Report Overview
The market for castrate-resistant prostate cancer therapeutics is anticipated to expand at a CAGR of 8.4% from 2023 to 2030.
Genetic predisposition, an unclean diet, the presence of the elderly population, exposure to medications, and having several sexual partners are a few risk factors for castration-resistant prostate cancer. Castration-resistant prostate cancer could be diagnosed using techniques such prostate imaging, tumour markers, biopsies, and staging tests. Docetaxel-based chemotherapy has received widespread support from urologists and oncologists for the treatment of CRPC. Prostate cancer, including castration-resistant prostate cancer, is becoming more common, which accelerates market expansion. In addition, the industry is primarily driven by the growing elderly population.
For More Insights request free Sample: https://www.datamintelligence.com/download-sample/castrate-resistant-prostate-cancer-therapeutics-market
Market Dynamics
The market is expanding as a result of the rising incidence of prostate cancer.
The market for prostate cancer therapies is expanding due to the increased prevalence of the disease worldwide. Except for skin cancer, prostate cancer most frequently affects men. In 2022, there will be 268,490 males in the United States who will receive a prostate cancer diagnosis, according to estimates made by the editorial board of Cancer.Net. The Net Editorial Board estimates that 1,414,259 men will receive prostate cancer diagnoses in 2020. It is the fourth most frequent cancer in the world, according to diagnoses. In the US, it is the second most common cause of cancer-related death in men. In 2020, 34,500 men worldwide lost their lives to prostate cancer, which claimed 375,304 lives in total.
Prostate cancer cases are more common in developed countries than in poor countries. The number of cancer patients is increasing, which raises the need for castrate-resistant prostate cancer therapies to reduce mortality risk and the tumor-damaging effects of the virus. Consumers throughout the world are very concerned about their health and are willing to spend a lot of money to improve their serious health concerns. During the projected period, there will be an increase in demand for castrate-resistant prostate cancer therapies due to increased cancer prevalence and rising average consumer purchasing power.
The market is expanding thanks to many medication approvals for castrate-resistant prostate cancer. Globally, the government is putting a lot more effort into selling castrate-resistant prostate cancer treatments. The market for castrate-resistant prostate cancer therapies has recently seen a number of advancements, including. The FDA approved Pluvicto in March 2022 for the treatment of metastatic castration-resistant prostate cancer using taxane-based chemotherapy and blocking the androgen receptor (AR) pathway.
The main obstacle to the market's expansion throughout the projection period, however, is the high cost of castrate-resistant prostate cancer treatment.
View Full Report: https://www.datamintelligence.com/research-report/castrate-resistant-prostate-cancer-therapeutics-market
Castrate Resistant Prostate Cancer Therapeutics Market Companies
Major players are Astellas Pharma, Inc., Bayer AG, Johnson & Johnson Services Inc., Pfizer Inc., Sanofi SA, GlaxoSmithKline PLC, Northwest Biotherapeutic, and Active Biotech AB, among others.
Related Reports:
Sign in to leave a comment.